ABSTRACT
Erythropoietic protoporphyria and X-linked protoporphyria are rare genetic photodermatoses. Limited expertise with these disorders among physicians leads to diagnostic delays. Here, we present evidence-based consensus guidelines for the diagnosis, monitoring, and management of erythropoietic protoporphyria and X-linked protoporphyria. A systematic literature review was conducted, and reviewed among subcommittees of experts, divided by topic. Consensus on guidelines was reached within each subcommittee and then among all members of the committee. The appropriate biochemical and genetic testing to establish the diagnosis is reviewed in addition to the interpretation of results. Prevention of symptoms, management of acute phototoxicity, and pharmacologic and nonpharmacologic treatment options are discussed. The importance of ongoing monitoring for liver disease, iron deficiency, and vitamin D deficiency is discussed with management guidance. Finally, management of pregnancy and surgery and the safety of other therapies are summarized. We emphasize that these are multisystemic disorders that require longitudinal monitoring. These guidelines provide a structure for evidence-based diagnosis and management for practicing physicians. Early diagnosis and management of these disorders are essential, particularly given the availability of new and emerging therapies.
Subject(s)
Dermatitis, Phototoxic , Genetic Diseases, X-Linked , Liver Diseases , Practice Guidelines as Topic , Protoporphyria, Erythropoietic , Humans , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/therapy , Genetic Diseases, X-Linked/genetics , Protoporphyria, Erythropoietic/diagnosis , Protoporphyria, Erythropoietic/genetics , Protoporphyria, Erythropoietic/therapyABSTRACT
BACKGROUND: Erythropoietic protoporphyria (EPP) is a rare disease that causes disabling cutaneous photosensitivity with pain and burning sensations. In 2019, afamelanotide, an α-melanocyte-stimulating hormone analogue, was approved in the United States for treatment of EPP. In this study, patients receiving afamelanotide filled out questionnaires assessing the benefit of treatment. Outcomes measured included: return to normal activities, experience of phototoxic reactions, effect on patient confidence, and more. Patients ranked their experience on a descriptive scale ranging from "very much" to "never". RESULTS: Prior to treatment, 75% of patients indicated that EPP affected their lives "very much" or "a lot". This number fell to 11% after the 1st implant and to 0% after each subsequent implant. The number of patients that willingly ventured outside increased with each subsequent implant. CONCLUSION: The results of this study clearly show that afamelanotide treatment can dramatically and positively impact the lives of EPP patients. Citation: Resnik SR, Targett D, Resnik BI. Into the light: afamelanotide and the treatment of erythropoietic protoporphyria in the United States. J Drugs Dermatol. 2023;22(9):941-949. doi:10.36849/JDD.7126R1.
Subject(s)
Dermatitis, Phototoxic , Protoporphyria, Erythropoietic , Humans , alpha-MSH/adverse effects , Protoporphyria, Erythropoietic/diagnosis , Protoporphyria, Erythropoietic/drug therapy , PainABSTRACT
BACKGROUND: Erythropoietic protoporphyria (EPP) is a rare disorder of heme biosynthesis hallmarked by early-onset photosensitivity and mainly due to defective ferrochelatase activity leading to increased erythrocyte protoporphyrin IX (PPIX) levels. Evidence regarding the relationship between erythrocyte PPIX concentration and photosensitivity is limited. METHODS: To investigate the relationship between free erythrocyte PPIX (FEP) concentration; routine laboratory tests, particularly iron metabolism biomarkers; and ultraviolet (UV) A/visible light phototesting findings, 20 genetically confirmed EPP and one XLPP treatment-naive patients were included in our study. They underwent UVA and visible light phototesting. On the same day, blood samples were collected for measurement of FEP, serum iron, transferrin, transferrin saturation, and ferritin, 25-hydroxyvitamin D, and liver enzyme levels. RESULTS: Median FEP concentration at the time of phototesting was 57.50 (IQR: 34.58-102.70) µg/g of Hb. UVA and visible light phototesting were positive in 9 (42.9%) and 8 (38.1%) patients, respectively. Median FEP concentration was significantly higher in UVA phototest-positive patients than in those negative (64.37 [IQR: 57.45-121.82] vs 45.35 [IQR: 24.53-74.61] µg/g of Hb, respectively; P = .04486). Similarly, UVA photosensitive individuals had significantly lower median serum iron levels (61.5 [IQR: 33.5-84] µg/dL vs 109 [IQR: 63.25-154] µg/dL, respectively; P = .01862) and transferrin saturation values (15.005 [IQR: 7.0775-18.41] % vs 29.645 [IQR: 17.8225-34.3575] %; P = .0109) than those negative. CONCLUSIONS: Our study demonstrates that UVA phototest positivity is associated with higher FEP concentration and lower transferrin saturation and serum iron concentration in EPP.
Subject(s)
Protoporphyria, Erythropoietic , Erythrocytes/metabolism , Humans , Protoporphyria, Erythropoietic/diagnosis , Protoporphyria, Erythropoietic/metabolism , Protoporphyrins/metabolism , Transferrins/metabolismABSTRACT
PURPOSE: Patients with erythropoietic protoporphyria (EPP), a severe painful photodermatosis, experience prodromal sensations when exposed to sunlight, which are the "warning signals" to exit the sun, as prolonged exposure causes an excruciatingly painful phototoxic attack. The unique prodromal cutaneous sensations are reversible and differ from the severe burning pain attack lasting 2-7 days. Previously, afamelanotide treatment was studied using time to pain or time outside as primary outcome measures. Since patients have an ingrained fear of sunlight, these measures did not capture the full treatment effect. We retrospectively characterized and evaluated time to prodrome (TTP) as a safer, patient-reported outcome (PRO) measure in afamelanotide-treated patients. METHODS: Structured interviews recorded TTP before and during afamelanotide treatment in retrospective US and Dutch cohort studies. RESULTS: Thirty-one US and 58 Dutch EPP patients participated. Before afamelanotide treatment, 54.8% US and 39.7% Dutch patients reported TTP onset <10 minutes in direct sunlight. In both studies, patients' TTP's were significantly longer during afamelanotide treatment (p < 0.0001). All US patients' TTP increased; no TTP was <10 minutes. Among Dutch patients 81% improved; only 10.3% reported TTPs < 10 minutes. CONCLUSION: EPP patients reported substantial improvements in TTP during afamelanotide treatment. TTP could provide a safer, PRO-based efficacy endpoint for assessing future EPP treatments.
Subject(s)
Protoporphyria, Erythropoietic , Sunlight , Humans , Pain , Patient Reported Outcome Measures , Protoporphyria, Erythropoietic/diagnosis , Protoporphyria, Erythropoietic/drug therapy , Retrospective Studies , Sunlight/adverse effectsABSTRACT
PURPOSE: Erythropoietic protoporphyria (EPP), characterized by painful cutaneous photosensitivity, results from pathogenic variants in ferrochelatase (FECH). For 96% of patients, EPP results from coinheriting a rare pathogenic variant in trans of a common hypomorphic variant c.315-48T>C (minor allele frequency 0.05). The estimated prevalence of EPP derived from the number of diagnosed individuals in Europe is 0.00092%, but this may be conservative due to underdiagnosis. No study has estimated EPP prevalence using large genetic data sets. METHODS: Disease-associated FECH variants were identified in the UK Biobank, a data set of 500,953 individuals including 49,960 exome sequences. EPP prevalence was then estimated. The association of FECH variants with EPP-related traits was assessed. RESULTS: Analysis of pathogenic FECH variants in the UK Biobank provides evidence that EPP prevalence is 0.0059% (95% confidence interval [CI]: 0.0042-0.0076%), 1.7-3.0 times more common than previously thought in the UK. In homozygotes for the common c.315-48T>C FECH variant, there was a novel decrement in both erythrocyte mean corpuscular volume (MCV) and hemoglobin. CONCLUSION: The prevalence of EPP has been underestimated secondary to underdiagnosis. The common c.315-48T>C allele is associated with both MCV and hemoglobin, an association that could be important both for those with and without EPP.
Subject(s)
Protoporphyria, Erythropoietic , Biological Specimen Banks , Europe , Ferrochelatase/genetics , Humans , Mutation , Protoporphyria, Erythropoietic/diagnosis , Protoporphyria, Erythropoietic/epidemiology , Protoporphyria, Erythropoietic/genetics , United Kingdom/epidemiologyABSTRACT
The erythropoietic porphyrias are inborn errors of heme biosynthesis with prominent cutaneous manifestations. They include autosomal recessive Congenital Erythropoietic Porphyria (CEP) due to loss-of-function (LOF) mutations in the Uroporphyrinogen III Synthase (UROS) gene, Erythropoietic Protoporphyria (EPP) due to LOF mutations in the ferrochelatase (FECH) gene, and X-Linked Protoporphyria (XLP) due to gain-of-function mutations in the terminal exon of the Aminolevulinic Acid Synthase 2 (ALAS2) gene. During the 11-year period from 01/01/2007 through 12/31/2017, the Mount Sinai Porphyrias Diagnostic Laboratory provided molecular diagnostic testing for one or more of these disorders in 628 individuals, including 413 unrelated individuals. Of these 628, 120 patients were tested for CEP, 483 for EPP, and 331 for XLP, for a total of 934 tests. For CEP, 24 of 78 (31%) unrelated individuals tested had UROS mutations, including seven novel mutations. For EPP, 239 of 362 (66%) unrelated individuals tested had pathogenic FECH mutations, including twenty novel mutations. The IVS3-48â¯Tâ¯>â¯C low-expression allele was present in 231 (97%) of 239 mutation-positive EPP probands with a pathogenic FECH mutation. In the remaining 3%, three patients with two different FECH mutations in trans were identified. For XLP, 24 of 250 (10%) unrelated individuals tested had ALAS2 exon 11 mutations. No novel ALAS2 mutations were identified. Among family members referred for testing, 33 of 42 (79%) CEP, 62 of 121 (51%) EPP, and 31 of 81 (38%) XLP family members had the respective family mutation. Mutation-positive CEP, EPP, and XLP patients who had been biochemically tested had marked elevations of the disease-appropriate porphyrin intermediates. These results expand the molecular heterogeneity of the erythropoietic porphyrias by adding a total of 27 novel mutations. The results document the usefulness of molecular testing to confirm the positive biochemical findings in these patients and to identify heterozygous family members.
Subject(s)
Ferrochelatase/genetics , Genetic Heterogeneity , Mutation , Porphyria, Erythropoietic/genetics , Protoporphyria, Erythropoietic/genetics , Uroporphyrinogen III Synthetase/genetics , Family , Female , Genetic Carrier Screening , Heme/biosynthesis , Humans , Male , Molecular Diagnostic Techniques , Photosensitivity Disorders/etiology , Protoporphyria, Erythropoietic/diagnosisABSTRACT
The porphyrias are a group of metabolic disorders resulting from an innate abnormality in haem biosynthesis, and the clinical settings of which vary according to the genetic enzyme abnormality in question. These are genetic disorders with autosomal dominant or recessive inheritance of varying penetrance, and whose clinical expression differs according to the preferential location of haem precursors. Different classifications have been proposed according to genetic inheritance, the enzyme anomaly at issue, and clinical expression. The clinical classification distinguishes between acute porphyria (acute intermittent porphyria, porphyria variegata, hereditary coproporphyria), bullous cutaneous porphyrias (porphyria cutanea tarda, porphyria variegata and hereditary coproporphyria), painful photosensitive acute cutaneous porphyrias (erythropoietic protoporphyria and X-linked dominant protoporphyria), and rare recessive porphyrias (congenital erythropoietic porphyria, Doss porphyria, hepatoerythropoietic porphyria and harderoporphyria). Treatment depends on the clinical expression of the disorder.
Subject(s)
Porphyrias , Skin Diseases, Metabolic , Biopsy , Coproporphyria, Hereditary/diagnosis , Coproporphyria, Hereditary/genetics , Coproporphyria, Hereditary/therapy , Diagnosis, Differential , Heme/biosynthesis , Humans , Photosensitivity Disorders/complications , Photosensitivity Disorders/diagnosis , Photosensitivity Disorders/therapy , Porphyria Cutanea Tarda/diagnosis , Porphyria Cutanea Tarda/genetics , Porphyria Cutanea Tarda/therapy , Porphyria, Erythropoietic/diagnosis , Porphyria, Erythropoietic/genetics , Porphyria, Erythropoietic/therapy , Porphyrias/classification , Porphyrias/diagnosis , Porphyrias/genetics , Porphyrias/therapy , Protoporphyria, Erythropoietic/diagnosis , Protoporphyria, Erythropoietic/genetics , Protoporphyria, Erythropoietic/therapy , Skin/pathology , Skin Diseases, Metabolic/classification , Skin Diseases, Metabolic/diagnosis , Skin Diseases, Metabolic/genetics , Skin Diseases, Metabolic/therapyABSTRACT
Erythropoietic protoporphyria is a photodermatosis presenting in childhood with severe pain on sun exposure. The diagnosis is often delayed because of the lack of awareness among pediatricians. We describe the diagnostic odyssey of 2 children presenting with symptoms of erythropoietic protoporphyria and report results of a survey of 129 affected individuals.
Subject(s)
Delayed Diagnosis , Hypersensitivity/diagnosis , Photosensitivity Disorders/diagnosis , Protoporphyria, Erythropoietic/diagnosis , Child, Preschool , Diagnosis, Differential , Female , Humans , Male , Photosensitivity Disorders/therapy , Prognosis , Protective Clothing , Protoporphyria, Erythropoietic/therapy , Recurrence , Risk Assessment , Severity of Illness Index , Sunlight/adverse effectsSubject(s)
Ferrochelatase/genetics , Liver/pathology , Porphyrins/blood , Protoporphyria, Erythropoietic/diagnosis , Adult , Biopsy , Genetic Testing , Humans , Liver Function Tests , Male , Mutation , Protoporphyria, Erythropoietic/blood , Protoporphyria, Erythropoietic/genetics , Protoporphyria, Erythropoietic/pathologyABSTRACT
X-linked protoporphyria (XLP), a rare erythropoietic porphyria, results from terminal exon gain-of-function mutations in the ALAS2 gene causing increased ALAS2 activity and markedly increased erythrocyte protoporphyrin levels. Patients present with severe cutaneous photosensitivity and may develop liver dysfunction. XLP was originally reported as X-linked dominant with 100% penetrance in males and females. We characterized 11 heterozygous females from six unrelated XLP families and show markedly varying phenotypic and biochemical heterogeneity, reflecting the degree of X-chromosomal inactivation of the mutant gene. ALAS2 sequencing identified the specific mutation and confirmed heterozygosity among the females. Clinical history, plasma and erythrocyte protoporphyrin levels were determined. Methylation assays of the androgen receptor and zinc-finger MYM type 3 short tandem repeat polymorphisms estimated each heterozygotes X-chromosomal inactivation pattern. Heterozygotes with equal or increased skewing, favoring expression of the wild-type allele had no clinical symptoms and only slightly increased erythrocyte protoporphyrin concentrations and/or frequency of protoporphyrin-containing peripheral blood fluorocytes. When the wild-type allele was preferentially inactivated, heterozygous females manifested the disease phenotype and had both higher erythrocyte protoporphyrin levels and circulating fluorocytes. These findings confirm that the previous dominant classification of XLP is inappropriate and genetically misleading, as the disorder is more appropriately designated XLP.
Subject(s)
Genes, X-Linked , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/genetics , Phenotype , Protoporphyria, Erythropoietic/diagnosis , Protoporphyria, Erythropoietic/genetics , X Chromosome Inactivation , Alleles , Erythrocytes/metabolism , Female , Genetic Diseases, X-Linked/metabolism , Genotype , Humans , Male , Mutation , Nuclear Proteins/genetics , Pedigree , Porphyrins/metabolism , Protoporphyria, Erythropoietic/metabolism , Protoporphyrins/metabolism , Receptors, Androgen/geneticsABSTRACT
BACKGROUND: Erythropoietic protoporphyria (EPP) is a rare genetic disease that causes severe sensitivity to visible light as a result of protoporphyrin IX (PpIX) accumulation in the skin. OBJECTIVES: To establish a noninvasive method to measure PpIX in the skin of patients with EPP and to investigate how skin PpIX relates to erythrocyte PpIX and photosensitivity. METHODS: Skin PpIX was measured in 25 patients with EPP by calculating the difference in PpIX fluorescence before and after complete photobleaching of PpIX using controlled illumination. The patients reported symptoms during the illumination and skin erythema was measured before and after illumination. Confirmation of the presence of PpIX was obtained in seven patients by measuring the in vivo fluorescence emission spectrum. This method was used to examine skin PpIX during the hours after an illumination in seven patients. RESULTS: We established a noninvasive method to measure skin PpIX based on measurements of PpIX fluorescence before and after complete PpIX photobleaching. The patients had an average skin PpIX of 2·0 units and skin emission spectra confirmed the presence of skin PpIX (peak emission 632 nm). Skin PpIX was associated with erythrocyte PpIX (P = 0·002, R2 = 0·34), skin erythema (P = 0·001, R2 = 0·47) and symptoms during illumination. Furthermore, skin PpIX increased during the hours after illumination. CONCLUSIONS: We have developed a noninvasive method to measure skin PpIX in patients with EPP. Skin PpIX is dependent on erythrocyte PpIX and exposure of the skin to light. This method can be used for objective monitoring of treatment effect.